Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TECH - Bio-Techne Corp


IEX Last Trade
74.03
-0.490   -0.662%

Share volume: 842,930
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$74.52
-0.49
-0.66%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
59%
Profitability 41%
Dept financing 33%
Liquidity 75%
Performance 80%
Company vs Stock growth
vs
Performance
5 Days
2.35%
1 Month
-9.54%
3 Months
-4.01%
6 Months
-0.12%
1 Year
-6.93%
2 Year
-9.95%
Key data
Stock price
$74.03
P/E Ratio 
69.82
DAY RANGE
$73.49 - N/A
EPS 
$1.05
52 WEEK RANGE
$51.31 - $85.39
52 WEEK CHANGE
-$0.05
MARKET CAP 
11.735 B
YIELD 
0.43%
SHARES OUTSTANDING 
158.600 M
DIVIDEND
$0.08
EX-DIVIDEND DATE
08/19/2024
NEXT EARNINGS DATE
10/31/2024
BETA 
1.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$715,768
AVERAGE 30 VOLUME 
$982,636
Company detail
CEO: Charles Kummeth
Region: US
Website: https://www.bio-techne.com/
Employees: 1,595
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Recent news